NDA 205912 · Praxair Distribution INC
Helium, Usp
Helium · Inhalation
Last checked: Nov 20, 2026Latest source record: Aug 5, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Aug 5, 2013
Approved uses
1
Original approval plus efficacy supplements
Registered trials
39
4 Phase 3, 0 recruiting
FAERS reports
50
46 serious, 33 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 15, 2025.
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 5, 2013 Original approval · Medical Gas Letter
1 products under this application
- HELIUM, USP · HELIUM N/A · GAS, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Helium" as an intervention, any sponsor and status, largest first.
- Efficacy of Helium/Oxygen Compared to Air/Oxygen in Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingTerminated
Air Liquide Santé InternationalIndustry
NCT01155310 · 446 participants · Start May 2010 · Primary completion Oct 2013
Drug: Helium/Oxygen 78%/22%; Air/Oxygen · For: Chronic Obstructive Pulmonary Disease
Sites: Brussels, Belgium; Yvoir, Belgium; Angers, France · 16 sites in all
Eric A. HoffmanAcademic, hospital or other
NCT03764163 · 341 participants · Start Sep 30, 1997 · Primary completion Jun 5, 2015
Drug: Xenon gas · For: Pulmonary Disease, Chronic Obstructive
Sites: Iowa City, Iowa
- Aripiprazole in Children and Adolescents With Bipolar I DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00110461 · 296 participants · Start Mar 2005 · Primary completion Feb 2007
Drug: Aripiprazole; Aripiprazole and 1 more · For: Bipolar Disorder
Sites: Scottsdale, Arizona; Little Rock, Arkansas; National City, California · 53 sites in all
- Development of a New Method for Steady-State Measurement of NO Lung Diffusing Capacity in Healthy SubjectsStatus unknown
University Hospital TuebingenAcademic, hospital or other
NCT00315965 · 107 participants (planned) · Start Jul 2006
Drug: Nitric oxide, Carbon monoxide, Helium · For: Pulmonary Diffusing Capacity
Sites: Tübingen, Germany
- Effect of Heliox on RSV BronchiolitisPivotal-lookingCompleted
Wael SeliemAcademic, hospital or other
NCT03171142 · 104 participants · Start May 1, 2015 · Primary completion Aug 1, 2016
Drug: Heliox; Air · For: RSV Infection; Acute Bronchiolitis
Imam Abdulrahman Bin Faisal UniversityAcademic, hospital or other
NCT03049605 · 65 participants · Start Jan 25, 2014 · Primary completion Jan 1, 2015
Drug: Only medical treatment · For: Diabetes
The First Hospital of Hebei Medical UniversityAcademic, hospital or other
NCT07053215 · 60 participants · Start Dec 1, 2020 · Primary completion Dec 1, 2024
Drug: Camrelizumab; Platinum-based doublet chemotherapy · For: Non-small Cell Lung Cancer (NSCLC)
Sites: Shijiazhuang, China
Fuda Cancer Hospital, GuangzhouAcademic, hospital or other
NCT02843581 · 60 participants · Start Jul 1, 2016 · Primary completion Jul 1, 2017
Drug: NK immunotherapy · For: Metastatic Esophageal Cancer
Sites: Guangzhou, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- completed suicide23
- asphyxia6
- overdose6
- toxicity to various agents5
- generalised tonic-clonic seizure4
- sedation4
- drug level increased3
- myalgia3
- off label use3
- abnormal behaviour2
- aggression2
- cataplexy2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2013 | 3 |
| 2014 | 7 |
| 2015 | 9 |
| 2016 | 3 |
| 2017 | 11 |
| 2018 | 2 |
| 2019 | 8 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Laparoscopic surgery for endometriosis.
Bafort C, Beebeejaun Y, Tomassetti C, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Laser therapy for treating hypertrophic and keloid scars.
Leszczynski R, da Silva CA, Pinto ACPN, et al. · Cochrane Database Syst Rev 2022 · Research Support, Non-U.S. Gov't, Systematic Review
- Comparative Efficacy of Bronchiolitis Interventions in Acute Care: A Network Meta-analysis.
Elliott SA, Gaudet LA, Fernandes RM, et al. · Pediatrics 2021 · Comparative Study, Research Support, Non-U.S. Gov't
- Aesthetic Nonexcisional Arm Contouring.
Ibrahiem SMS · Aesthet Surg J 2022 · Randomized Controlled Trial
- Asthma in adults.
Dennis RJ, Solarte I, Rodrigo G · BMJ Clin Evid 2010 · Systematic Review
- Helium-oxygen reduces work of breathing in mechanically ventilated patients with chronic obstructive pulmonary disease.
Gainnier M, Arnal JM, Gerbeaux P, et al. · Intensive Care Med 2003 · Clinical Trial, Randomized Controlled Trial
Sponsor: Praxair Distribution INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.